Recommendation of the President – Intuniv (guanfacine)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 103/2025 on the validity of granting authorizations for the reimbursement of the medicinal product Intuniv (guanfacine) for the following indications: attention deficit hyperactivity disorder (ADHD), Tourette syndrome, Tourette syndrome with concomitant attention deficit hyperactivity disorder